Statin use is not associated with liver related mortality

Younoszai, Zahra; Li, Zheng; Stepanova, Maria; Erario, Madeline; Cable, Rebecca; Younossi, Zobair M.

doi:10.1016/s1665-2681(19)30908-1

Cited by 13 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these, 28 were finally included for meta-analysis ( Fig. 1 ): 22 - 49 22 were cohort studies and six nested case-control studies; 18 studies were from Asia, five were from the United States, and the other five were from Europe.…”

Section: Resultsmentioning

confidence: 99%

Systematic Review with Meta-Analysis: Low-Level Alcohol Consumption and the Risk of Liver Cancer

et al. 2020

View full text Add to dashboard Cite

Background/Aims: Multiple meta-analyses and observational studies have reported that alcohol is a risk factor for liver cancer. However, whether there is a safe level of alcohol consumption remains unclear. We performed a systematic review and meta-analysis of the correlation between low-level alcohol consumption and the risk of liver cancer. Methods: Nested case-control studies and cohort studies involving the general population published prior to July 2019 were searched. In total, 28 publications (31 cohorts) with 4,899 incident cases and 10,859 liver cancer-related deaths were included. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Results: Compared with those with low levels of alcohol consumption, moderate and heavy drinkers (≥1 drink/day for females and ≥2 drinks/day for males) had pooled ORs of 1.418 (95% CI, 1.192 to 1.687; p<0.001) for liver cancer incidence and 1.167 (95% CI, 1.056 to 1.290; p=0.003) for liver cancer mortality. The pooled OR for liver disease-related mortality for those with more than low levels of alcohol consumption was 3.220 (95% CI, 2.116 to 4.898; p<0.001) and that for all-cause mortality was 1.166 (95% CI, 1.065 to 1.278; p=0.001). The sensitivity analysis showed that none of the studies had a strong effect on the pooled OR. The Egger test, Begg rank correlation test, and the funnel plot showed no overt indication of publication bias. Conclusions: Continuous consumption of more than a low-level of alcohol (≥1 drink/day for females and ≥2 drinks/ day for males) is related to a higher risk of liver cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic Review with Meta-Analysis: Low-Level Alcohol Consumption and the Risk of Liver Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[35][36][37] The information on the cause of death was not available in the database but it is plausible that the non-users may develop HCC related deaths while the statin users may die from other causes. Although statin users may be at high risk of nonliver death and those died during the exposure period were excluded, the absence of mortality benefit was consistently seen in the 1-year and 3-year landmark analysis (Table 3).…”

Section: Discussionmentioning

confidence: 99%

Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis

Hsiang

Wong

Tse

et al. 2015

Journal of Hepatology

View full text Add to dashboard Cite

“…In fact, the rate of liver-related mortality was significantly lower among statin users compared to nonstatin users. [ 41 ] Analysis of cases of hepatotoxicity associated with statin use in Spanish hepatotoxicity registry revealed that statins are not a common cause of hepatotoxicity in Spain and atorvastatin seems to be the most commonly involved statin agent. [ 37 ]…”

Section: Nature and Incidence Of Hepatic Adverse Effectsmentioning

confidence: 99%

Statins and its hepatic effects: Newer data, implications, and changing recommendations

José

2016

J Pharm Bioall Sci

View full text Add to dashboard Cite

Hepatic adverse effects are one of the most commonly known adverse effects reported with statins. Frequently, fear of serious hepatic effects contributes to underutilization of statins as well as unnecessary discontinuation of its use among those indicated. There are changing data on the occurrence of these negative hepatic effects, recommendations on their actual risk, monitoring required, and safety of use in those with preexisting hepatic disorders. Based on reviewed literature, statins appear to be associated with a very low risk of true and serious liver injury. Unprecedented fears regarding hepatic adverse effects of statins among prescribers and patients can deny patients of the significant benefits of these agents. Routine periodic monitoring of liver function does not appear to detect or prevent serious liver injury and hence may not be indicated. But the potential of statins to cause significant and serious hepatic effects should not be overlooked in daily clinical practice. Statin use need not be avoided in patients with preexisting liver dysfunction such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, compensated cirrhosis, and compensated chronic liver disease if its use is clearly indicated. Physician's judgment based on the risk and benefit for an individual patient does matter when a strategy is chosen regarding the use of statins and monitoring patients while on statins.

show abstract

Statin use is not associated with liver related mortality

Cited by 13 publications

References 16 publications

Systematic Review with Meta-Analysis: Low-Level Alcohol Consumption and the Risk of Liver Cancer

Systematic Review with Meta-Analysis: Low-Level Alcohol Consumption and the Risk of Liver Cancer

Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis

Statins and its hepatic effects: Newer data, implications, and changing recommendations

Contact Info

Product

Resources

About